[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Atlantic Health System\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":279},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,41,66,98,130,151,173,200,226,254],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100642249","phase-3-implementation-of-vancomycin-powder-application-in-the-emergency-department-for-open-fractures-100642249",false,"NCT07659886","Implementation of Vancomycin Powder Application in the Emergency Department for Open Fractures","Inclusion Criteria:\n\n* Participants aged 18 years or older presenting to the Emergency Department with Gustilo-Anderson Type I, II, or III open fractures.\n\nExclusion Criteria:\n\n* Known allergy to vancomycin\n* Ballistic open fractures\n* Pregnancy\n* Currently breastfeeding\n* Age younger than 18 years.","ALL","18 Years",{"count":18,"type":19},100,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","To evaluate the feasibility, safety, and potential efficacy of applying vancomycin powder locally to open fractures in the emergency department prior to definitive surgical intervention.",[25],"Open Fracture",[27],"open fracture","NOT_YET_RECRUITING","2026-06-17",{"date":31,"type":32},"2026-06-22","ACTUAL",{"date":34,"type":19},"2026-06-10",{"date":36,"type":19},"2027-06-10",{"name":38,"class":39},"Atlantic Health System","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":16,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":20,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":40},"100637887","phase-4-silodosin-for-urinary-symptoms-in-female-patients-with-multiple-sclerosis-100637887","NCT07614321","Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis","Is Silodosin Effective for Treating Lower Urinary Tract Symptoms in Female Patients With Multiple Sclerosis? A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Female patients with a diagnosis of multiple sclerosis\n2. Age \\> 18\n3. Moderate to severe lower urinary tract symptoms as defined by an AUASS score \\> 8\n4. No UTI\n\nExclusion Criteria:\n\n1. Treatment with alpha-blocker, B3 agonist, or anticholinergic medication within the last 6 weeks\n2. Treatment with sacral neuromodulation, bladder Botox, or posterior tibial nerve stimulation within the last 9 months\n3. Renal impairment with CrCl \\\u003C 30\n4. PVR \\> 300\n5. Diagnosed orthostatic hypotension\n6. Pregnancy or breastfeeding\n7. Severe liver impairment (Child-Pugh class C)\n8. Current symptomatic kidney stones\n9. Recent MS relapse within the last 3 months\n10. Recent treatment with steroids in the last 3 months (this does not include one-time pre-treatment with steroids for administration of immunologic drug)","FEMALE",{"count":50,"type":19},60,[52],"PHASE4","The goal of this clinical trial is to learn if silodosin works to treat lower urinary tract symptoms (LUTS) in female patients with multiple sclerosis (MS). It will also learn about the effect of the drug on voiding parameters. The main questions it aims to answer are:\n\nDoes silodosin improve lower urinary tract symptoms based on questionnaires? Does silodosin change Uroflowmetry parameters in female patients with MS? Researchers will compare silodosin to a placebo (a look-alike substance that contains no drug) to see if silodosin works to treat LUTS in female patients with MS.\n\nParticipants will:\n\nTake silodosin or a placebo every day for 8 weeks Visit the clinic before initiating the medication and after 8 weeks of taking the medication for questionnaires and tests",[55,56],"Multiple Sclerosis","Lower Urinary Track Symptoms","RECRUITING","2026-05-26",{"date":60,"type":32},"2026-05-29",{"date":62,"type":19},"2026-04",{"date":64,"type":19},"2028-04",{"name":38,"class":39},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":74,"enrollmentInfo":75,"targetDuration":77,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":85,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},"100616701","pre-emptive-lava-ecmo-for-complex-high-risk-tavr-100616701","NCT07309029","Pre-Emptive LAVA-ECMO for Complex High-Risk TAVR","PROspective Evaluation of Pre-empTive Left Atrial Venoarterial Extra-Corporeal Membrane oxygenaTion for Complex High-risk Transcatheter Aortic Valve Replacement: PROTECT-TAVR","PROTECT-TAVR","Inclusion Criteria:\n\n\\- Patients are required to have either a Class III hemodynamic status OR type B or type C anatomical complexity with Class II (at risk) hemodynamics (Figure 2).\n\n* Hemodynamic Criteria\n\n  * Major Criteria (Class III)\n\n    * Systolic blood pressure \\\u003C90 mmHg or MAP\\\u003C60 mmHg\n    * Need for vasopressors or inotropes to maintain MAP\\>60 mmHg\n    * Evidence of end-organ damage including: acute kidney injury, liver dysfunction, elevated lactate or altered mentation\n  * Minor Criteria (Class II)\n\n    * Left ventricular ejection fraction \\\u003C35%\n    * Pulmonary hypertension (pulmonary artery systolic pressure \\>60 mmHg) with right ventricular dysfunction\n    * Pulmonary capillary wedge pressure \\>30 mmHg\n* Anatomic criteria\n\n  * Major Criteria (Type C)\n\n    * Native or valve-in-valve TAVR requiring single-leaflet modification for a large area of myocardium at risk (e.g. patients with large or dominant left circulation)\n    * Native or valve-in-valve TAVR requiring dual-leaflet modification\n    * Severe bioprosthetic aortic regurgitation\n    * Severe 3-vessel coronary artery disease not amenable to revascularization (SYNTAX score \\>33)\n  * Minor Criteria (Type B)\n\n    * Native or valve-in-valve TAVR requiring single-leaflet modification\n    * Severe commissural misalignment requiring leaflet modification\n    * High-risk for coronary occlusion not amenable to leaflet modification\n    * Critical low-flow low-gradient aortic stenosis (defined as an estimated aortic valve area ≤0.5 cm2)\n\nExclusion Criteria:\n\n* Age \\\u003C18 or pregnant\n\n  * General absolute contraindications to TAVR\n  * Severe peripheral artery disease with infeasibility for veno-arterial extracorporeal membrane oxygenation implantation.\n  * Contraindications to transeptal cannulation (e.g. pre-existing interatrial septum occluder device).\n  * Pre-existing Impella treatment.\n  * Onset of shock \\>12 hours.\n  * Preceding cardiac arrest with prolonged resuscitation (\\>40 minutes).\n  * Other severe concomitant disease with life expectancy \\\u003C6 months.\n  * Participation in another trial with an intervention.\n  * Any class I hemodynamic status\n  * Type A anatomical complexity with class I or II hemodynamic status","100 Years",{"count":76,"type":19},30,"30 Days","OBSERVATIONAL","The goal of this clinical trial is to evaluate the feasibility, effectiveness, and safety of pre-emptive left atrial veno-arterial extracorporeal membrane oxygenation (LAVA-ECMO) in patients undergoing complex and high-risk transcatheter aortic valve replacement (TAVR). These patients include adults with severe aortic stenosis who are hemodynamically unstable or at risk of instability due to anatomical complexity. The main questions it aims to answer are:\n\n1. Does pre-emptive LAVA-ECMO reduce the incidence of in-hospital death, intraprocedural cardiac arrest, or emergent cardiac surgery?\n2. What are the safety outcomes related to LAVA-ECMO, including major vascular, bleeding, or cardiac structural complications? -This is a single-arm, prospective, multi-center study with no comparison group.\n\nParticipants will:\n\n* Be screened for eligibility based on hemodynamic status and anatomical complexity\n* Undergo pre-emptive LAVA-ECMO cannulation prior to or during TAVR\n* Receive follow-up assessments at 30 days and 1 year, including clinical evaluation and echocardiography",[81,82,83,84],"Severe Aortic Stenosis","Cardiogenic Shock","Cardiogenic Shock, ECMO","Trans-catheter Aortic Valve Implantation",[86,87,88],"severe aortic stenosis","cardiogenic shock","TAVR","2025-12-15",{"date":91,"type":32},"2025-12-30",{"date":93,"type":19},"2026-01-01",{"date":95,"type":19},"2027-06-30",{"name":38,"class":39},2,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":20,"phases":109,"briefSummary":111,"conditions":112,"keywords":118,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":97},"100549868","atlantic-lipid-lowering-treatment-optimization-program-100549868","NCT06439654","Atlantic Lipid Lowering Treatment Optimization Program","Atlantic Lipid Lowering Treatment Optimization Program (ALLTOP): A Comprehensive Approach to the Treatment of Familial Hypercholesterolemia and Complex Dyslipidemias","ALLTOP","Inclusion Criteria:\n\n* LDL-C ≥160 mg\u002FdL\n* Untreated LDL-C ≥190 with family history of CAD\n* Prior MI and currently without optimized lipid-lowering therapy\n* Family history of CAD in first degree relative\n* Personal history of CAD\n* Untreated triglycerides \\>500\n* Elevated Lp(a) and\u002For high calcium scores\n* Consenting individuals\n\nExclusion Criteria:\n\n* Individuals who are pregnant\n* Individuals who are incarcerated\n* Individuals with a terminal illness\n* Individuals who do not consent","120 Years",{"count":108,"type":19},250,[110],"NA","Hypercholesterolemia is recognized as the major driver for cardiovascular morbidity and mortality. To help address this in our community, Atlantic Medical Group (AMG) formed a lipid workgroup chaired by Robert D. Fishberg, MD, and Jeffrey N. Feldman, MD. The overarching goal of the lipid workgroup is to enhance the treatment of lipid disorders in those patients with abnormal lipid levels by improving access to resources at the primary care practice level and specialty level. We aim to develop a model for primary and secondary prevention that integrates guidelines for treatment at the practice level. Our primary objective is to identify high-risk patients by utilizing the electronic health record and partnering with patients' primary care providers to provide comprehensive medical management.",[113,114,115,116,117],"Familial Hypercholesterolemia","Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia","Apolipoprotein B 100, Familial Defective","High Density Lipoprotein Deficiency","Low-Density-Lipoid-Type Hyperlipoproteinemia",[119,120,121],"LDL-C","FH","complex dyslipidemia","2025-07-30",{"date":124,"type":32},"2025-08-03",{"date":126,"type":32},"2024-07-01",{"date":128,"type":19},"2027-12-31",{"name":38,"class":39},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":20,"phases":138,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":40},"100589991","early-phase-1-a-novel-method-for-determination-of-thromboembolic-stroke-origin-100589991","NCT06961604","A Novel Method for Determination of Thromboembolic Stroke Origin","Inclusion Criteria: 18 years of age or older with a non-cardiogenic thromboembolic stroke in the past 14 days.\n\nExclusion Criteria: Less than 18 years of age, any other kind of stroke, not clinically stable to undergo PET-CT",{"count":137,"type":19},20,[139],"EARLY_PHASE1","Rupture of vulnerable carotid, vertebral, and intracranial arterial plaques results in thromboembolic stroke. Identification of these culprit lesions is an important component of post-stroke care. This study seeks to test the feasibility of NaF PET-CT to detect these plaques and alter patient care. Prior studies have shown a high degree of correlation between NaF PET+ lesions and high-risk plaque features on high resolution MRI, including mirocalcification, necrosis, and ulceration.",[142],"Thromboembolic Stroke","2025-05-06",{"date":145,"type":32},"2025-05-08",{"date":147,"type":19},"2025-06-01",{"date":149,"type":19},"2026-05-31",{"name":38,"class":39},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":48,"minAge":16,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":20,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":40},"100536200","the-effectiveness-of-prophylactic-antibiotics-for-urethral-bulking-100536200","NCT06261736","The Effectiveness of Prophylactic Antibiotics for Urethral Bulking","Inclusion Criteria:\n\n* Patients scheduled to undergo a urethral bulking procedure\n* Age 18 ≥ over\n\nExclusion Criteria:\n\n* History of recurrent urinary tract infections\n* Known history of urinary retention\n* Allergies or contraindications to multiple antibiotics\n* Inability to tolerate oral antibiotics\n* Concomitant surgical procedures at the time of urethral bulking\n* Pregnant or breastfeeding",{"count":158,"type":19},70,[110],"The goal of this clinical trial is to evaluate if prophylactic antibiotics in urethral bulking are effective in reducing postprocedural urinary tract infections.",[162,163,164],"Stress Urinary Incontinence","Postoperative Urinary Tract Infection","Urethral Bulking","2025-04-04",{"date":167,"type":32},"2025-04-08",{"date":169,"type":32},"2023-10-24",{"date":171,"type":19},"2026-01",{"name":38,"class":39},{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":180,"sex":48,"minAge":16,"maxAge":74,"enrollmentInfo":181,"targetDuration":4,"studyType":20,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":40},"100578391","is-methenamine-prophylaxis-for-urinary-tract-infection-after-midurethral-sling-as-effective-as-antibiotic-prophylaxis-100578391","NCT06810687","Is Methenamine Prophylaxis for Urinary Tract Infection After Midurethral Sling as Effective as Antibiotic Prophylaxis?","Is Methenamine Prophylaxis for Urinary Tract Infection After Midurethral Sling as Effective as Antibiotic Prophylaxis? A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Female\n2. Age ≥ 18\n3. Patients undergoing mid-urethral sling procedure\n\nExclusion Criteria:\n\n1. Medication intolerance or allergy to study medications\n2. Renal impairment with GFR \\\u003C30\n3. Breast feeding\n4. Pregnancy\n5. Recurrent urinary tract infections\n6. Active urinary tract infection\n7. Immunosuppressive disease\n8. Interstitial cystitis",true,{"count":182,"type":19},190,[110],"Stress urinary incontinence (SUI) affects at least 40% of women in the United States. Synthetic polypropylene mid-urethral slings (MUS) are the gold standard treatment for SUI. Post-operative urinary tract infections (UTI) are one of the most common complications after MUS placement. Some studies have demonstrated that MUS placement can increase the risk of UTI up to 21-34%.\n\nPost-operative UTI can lead to significant healthcare and patient burden. This additional burden further contributes to an estimated annual cost of $1.6 billion for UTI management in the United States. With increased antibiotic usage, there is simultaneous increase in bacterial resistance leading to treatment refractory UTI.\n\nThe investigators prescribe post-operative antibiotics prophylactically for 3 days after MUS placement with or without concurrent pelvic reconstructive surgery based on prior literature recommending post-operative prophylaxis. There is a greater emphasis on limiting antibiotic use given the trend of development of bacterial resistance. There are studies supporting alternatives such as methenamine for recurrent UTI prophylaxis treatment, but there are limited studies evaluating methenamine for UTI prophylaxis after MUS.",[186],"Urinary Tract Infection (Diagnosis)",[188,189,190,191],"urinary tract infection","midurethral sling","prophylaxis","methenamine","2025-02-05",{"date":194,"type":32},"2025-02-07",{"date":196,"type":32},"2025-01-30",{"date":198,"type":19},"2028-01-30",{"name":38,"class":39},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":207,"minAge":16,"maxAge":4,"enrollmentInfo":208,"targetDuration":210,"studyType":78,"phases":4,"briefSummary":211,"conditions":212,"keywords":214,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":40},"100572849","assessing-the-relationship-between-symptoms-and-mitral-regurgitnant-severity-100572849","NCT06738615","Assessing the Relationship Between Symptoms and Mitral Regurgitnant. Severity","Assessing the Impact of Diastolic Dysfunction on the Presence of Symptoms in Patients with Primary Mitral Regurgitation.","Inclusion Criteria:\n\n* Age \\>=18 years of age\n* Able to give informed consent\n* Primary (degenerative) mitral regurgitation\n* LVEF \\>=50%\n* Undergoing cardiac catheterization\n* Able to exercise on a treadmill\n\nExclusion Criteria:\n\n* Unable to give informed consent\n* Secondary (functional) mitral regurgitation\n* LVEF \\\u003C50%\n* Known coronary artery stenosis \\>=70% or past revascularization\n* More than mild aortic stenosis, mitral stenosis, aortic regurgitation, tricuspid regurgitation, or pulmonic regurgitation\n* Hypertrophic cardiomyopathy\n* Pregnancy","MALE",{"count":209,"type":19},40,"1 Year","The current American College of Cardiology\u002FAmerican Heart Association (ACC\u002FAHA) guidelines recommend surgery in patient with mitral regurgitation (MR) based on 1) the severity of MR and 2) the presence or absence of symptoms. Studies have shown that Cardiovascular Magnetic Resonance (CMR) is an accurate method to quantify the severity of MR. However, studies have also shown that symptoms are not necessarily related to the presence of symptoms. Thus, there appears to be a disconnect between the severity of MR and symptoms. Recent analysis of our data has shown that females and older patients with smaller ventricles, lower stroke volumes, and lower regurgitant volume relative to regurgitant fraction tend to be symptomatic. These findings suggest that decreased left ventricular compliance, i.e. diastolic dysfunction, may play an important role as an etiology of symptoms in patients with mitral regurgitation. The aim of this study is to study the presence of diastolic dysfunction in patients with MR and its association with symptom burden and exercise capacity.",[213],"Mitral Insufficiency",[215,216,217],"mitral regurgitation","symptoms","exercise capacity","2024-12-13",{"date":220,"type":32},"2024-12-17",{"date":222,"type":19},"2025-01-02",{"date":224,"type":19},"2027-05-02",{"name":38,"class":39},{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":180,"sex":48,"minAge":16,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":20,"phases":234,"briefSummary":235,"conditions":236,"keywords":241,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":40},"100556828","evaluation-of-a-postcoital-sponge-on-self-reported-vaginal-health-parameters-100556828","NCT06530186","Evaluation of a Postcoital Sponge on Self-Reported Vaginal Health Parameters","Inclusion Criteria:\n\n* Over 18 (for pH subset, 18-45)\n* Sexually-active with biological men\n* Willing and able to use product\n* Resides in continental USA\n* Understands, reads, writes, and speaks English\n\nExclusion Criteria:\n\n* Currently Pregnant or are trying to conceive\n* Unable to use device due to poor motor function\n* Unable to sign informed consent",{"count":233,"type":19},1000,[110],"LiviWell has developed a product designed for postcoital semen absorption. Previous studies have demonstrated the product rapidly absorbs semen, and leads to less symptoms of postcoital vaginal microbiome disruption such as vaginal odor and discharge. This study will investigate the study device, Livi, in a broader clinical setting.",[237,238,239,240],"Vaginal Infection","Vaginal Discharge","Vaginosis","Sexual Dysfunction",[242,243,244,245],"vaginal odor","vaginal discharge","postcoital dripping","vaginal microbiome","2024-07-27",{"date":248,"type":32},"2024-07-31",{"date":250,"type":19},"2024-08-01",{"date":252,"type":19},"2025-01-31",{"name":38,"class":39},{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":180,"sex":48,"minAge":16,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":20,"phases":263,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":40},"100479137","phase-4-use-of-prophylactic-antibiotics-prior-to-onabotulinumtoxina-100479137","NCT05519072","Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA","Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA Treatment of Overactive Bladder: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Female\n* Age ≥ 18\n* Patient undergoing bladder Botox treatment\n\nExclusion Criteria:\n\n* Pregnant and\u002For breastfeeding\n* Contraindication to injection of Botox - hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation, symptomatic urinary retention or post void residual (PVR) \\> 200 mL, unwillingness or inability to initiate clean intermittent catheterization (CIC) post-treatment if required.\n* Contraindication to oral antibiotics - hypersensitivity or allergy\n* Inability to take medication by mouth",{"count":262,"type":19},140,[52],"This study aims to show that lack of antibiotic prophylaxis to those undergoing bladder Botox injections is not significantly inferior to administering prophylaxis. By proving this, the investigators aim to decrease antibiotic use in this setting to combat the growing issue of antibiotic resistance.\n\nParticipants will be randomized to antibiotic or no treatment arm. Those randomized to the treatment arm will receive oral antibiotics for 2 days pre-treatment, on the treatment day, and 2 days post-treatment. Participants will return for a follow up appointment approximately 2 weeks after treatment to assess for urinary tract infection (UTI) symptoms. They will be called again at 6 weeks for follow up.",[266],"Antibiotic Prophylaxis",[268,269,270],"Antibiotics","Botox","OnabotulinumtoxinA","2024-03-25",{"date":273,"type":32},"2024-03-27",{"date":275,"type":32},"2022-08-16",{"date":277,"type":19},"2024-08-16",{"name":38,"class":39},""]